•  
• Tweet
•  
•  
• 

Fidelity Biosciences, the bioscience investing arm of Fidelity Investments has merged with technology venture capital fund Devonshire Investors’ to become F-Prime Capital. F-Prime Capital will serve as a unified venture investing unit for FMR, the parent company of Fidelity Investments and will focus on backing life sciences, healthcare and technology companies.

“The two entities were already working together pretty extensively, so we thought it made since to join them,” says Michael Aalto, a spokesman for F-Prime Capital in an interview. “Fidelity has a long history in venture and this will allow us to present a clearer market presence.”

The name F-Prime Capital is designed to distinguish the firm from Fidelity’s considerable mutual fund business.

F-Prime will be stage agnostic in terms of its investment. Aalto adds that in addition to biotech, F-Prime will opportunistically consider investments in some FinTech companies. “There’s a lot of opportunity in that sector right now and we have some people on the team with unique expertise in that area,” he explains.

To date, the firms that make up F-Prime have invested in more than 89 companies across five funds. Portfolio companies include patient-scheduling software company Kyruus and tuition payments company Flywire.